Literature DB >> 15790478

Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii.

Vera Loizzi1, Gennaro Cormio, Leonardo Resta, Nicola Fattizzi, Mario Vicino, Luigi Selvaggi.   

Abstract

BACKGROUND: Struma ovarii is a rare form of ovarian neoplasm composed entirely and predominantly of thyroid tissue. The association of pseudo-Meigs syndrome, elevation of CA125 and hyperthyroidism to struma ovarii is a rare condition. CASE: We report an unusual presentation of a postmenopausal woman with benign struma ovarii associated with pseudo-Meigs syndrome, hypertiroidism, and elevated CA125 serum level, and a large complex right pelvic mass thereby mimicking an ovarian cancer.
CONCLUSIONS: Struma ovarii is a rare cause of ascites, hydrothorax, elevated CA125, and hyperthyroidism. This rare condition should be considered in the differential diagnosis in patients with ascites and pleural effusions but with negative cytology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790478     DOI: 10.1016/j.ygyno.2004.12.040

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Struma ovarii associated with pseudo-Meigs' syndrome and elevated serum CA 125: a case report and review of the literature.

Authors:  Wei Jiang; Xin Lu; Zhi Ling Zhu; Xi Shi Liu; Cong Jian Xu
Journal:  J Ovarian Res       Date:  2010-07-29       Impact factor: 4.234

Review 2.  Struma Ovarii with Pseudo-Meigs' Syndrome and Raised Cancer Antigen-125 Levels Masquerading as an Ovarian Carcinoma Case report and literature review.

Authors:  Surekha Yadav; Reena Tomar; Nidhi Verma; Nita Khurana; Rewa Triathi
Journal:  Sultan Qaboos Univ Med J       Date:  2017-06-20

Review 3.  Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.

Authors:  Erin F Wolff; Marybeth Hughes; Maria J Merino; James C Reynolds; Jeremy L Davis; Craig S Cochran; Francesco S Celi
Journal:  Thyroid       Date:  2010-09       Impact factor: 6.568

4.  Bilateral Ovarian Fibrothecoma Associated with Ascites, Bilateral Pleural Effusion, and Marked Elevated Serum CA-125.

Authors:  Védi André Serges Loué; Eléonore Gbary; Sylvanus Koui; Bédi Akpa; Adélaide Kouassi
Journal:  Case Rep Obstet Gynecol       Date:  2013-02-03

5.  Struma ovarii associated with Pseudo-Meig's syndrome and high serum level of CA 125; a case report.

Authors:  Nahid Mostaghel; Anahita Enzevaei; Khandan Zare; Masoome Fallahian
Journal:  J Ovarian Res       Date:  2012-03-21       Impact factor: 4.234

6.  Coexistence of benign struma ovarii, pseudo-Meigs' syndrome and elevated serum CA 125: Case report and review of the literature.

Authors:  Chengjuan Jin; Ruiying Dong; Hualei Bu; Mingyuan Yuan; Youzhong Zhang; Beihua Kong
Journal:  Oncol Lett       Date:  2015-02-03       Impact factor: 2.967

7.  Struma ovarii: role of imaging?

Authors:  Martine I Dujardin; Priti Sekhri; Lindsay W Turnbull
Journal:  Insights Imaging       Date:  2013-12-20

8.  Demons-meigs pseudosyndrome mimicking the symptoms of pregnancy: a case report.

Authors:  Erdogan Nohuz; Maher Alaboud; Bilal El-Drayi; Stefano Tamburro; Said Kachkach; Janos Varga
Journal:  J Reprod Infertil       Date:  2014-10

9.  Management of malignant struma ovarii: is aggressive therapy justified? Case report and literature review.

Authors:  Letiția Leuștean; Maria-Christina Ungureanu; Cristina Preda; Stefana Catalina Bilha; Florin Obrocea; Radu Dănilă; Laura Stătescu; Delia Gabriela Apostol Ciobanu
Journal:  Thyroid Res       Date:  2022-08-11

Review 10.  Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of 131I scintigraphy and 18F-FDG PET: case report and review of the literature.

Authors:  Sayaka Fujiwara; Hideaki Tsuyoshi; Toshiya Nishimura; Nozomu Takahashi; Yoshio Yoshida
Journal:  J Ovarian Res       Date:  2018-02-02       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.